Enzon Returns Rights to Transplantation Product to Fresenius Biotech.BRIDGEWATER, N.J. -- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that it is returning its rights to ATG-Fresenius S to Fresenius Biotech bi·o·tech n. Informal Biotechnology. biotech Noun short for biotechnology Noun 1. GmbH, a subsidiary of the health care company Fresenius AG. ATG-Fresenius S is a polyclonal antibody Polyclonal antibodies are antibodies that are derived from different B-cell lines. They are a mixture of immunoglobulin molecules secreted against a specific antigen, each recognising a different epitope. preparation used for T-lymphocyte suppression to prevent organ graft rejection graft rejection Rejection Clinical immunology The constellation of defenses mounted by the immune system of the recipient of an allograft–eg kidney, liver, pancreas, etc, which compromise the continued viability of grafted tissue. Cf Graft. in organ transplant organ transplant: see transplantation, medical. patients. The companies are committed to working together to assure a smooth transition for the current ongoing clinical trial for ATG-Fresenius S. Enzon's decision to return full rights to Fresenius Biotech was based on its ongoing efforts to redirect re·di·rect tr.v. re·di·rect·ed, re·di·rect·ing, re·di·rects To change the direction or course of. n. A redirect examination. re its research and development investments to projects strategically aligned with its business objectives, including an increasing focus on cancer and adjacent therapeutic areas. About Enzon Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics to treat patients with cancer and other life-threatening diseases. Enzon's specialized sales force markets ABELCET(R), ONCASPAR(R), ADAGEN(R), and DEPOCYT(R) in North America North America, third largest continent (1990 est. pop. 365,000,000), c.9,400,000 sq mi (24,346,000 sq km), the northern of the two continents of the Western Hemisphere. . In addition, Enzon also receives royalties on sales of PEG-INTRON(R), marketed by Schering-Plough Corporation, and MACUGEN(R), marketed by OSI Pharmaceuticals OSI Pharmaceuticals, Inc. is an American pharmaceutical company based in Long Island, New York with facilities in Colorado, New Jersey and the United Kingdom. They specialize in the discovery and development of molecular targeted therapies, and are listed in the NASDAQ and Pfizer Inc. Enzon's product-driven strategy includes an extensive drug development program that leverages its proprietary technologies, including a next-generation PEGylation platform that utilizes linkers designed to release compounds at a controlled rate. Enzon complements its internal research and development efforts with strategic initiatives, such as partnerships designed to broaden its revenue base or provide access to promising new technologies or product development opportunities. Further information about Enzon and this press release can be found on the Company's web site at www.enzon.com. All information in this press release is as of January 6, 2005 and the Company undertakes no duty to update this information. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion